Skip to main content
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. logo

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300255 ISIN · CNE1000016C2 LEI · 836800E53822RNN6OA77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,562 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300255

About Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

https://www.hbcsbio.com

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and marketing of heparin-based pharmaceutical products. The company maintains a comprehensive industrial chain, spanning from the collection of crude heparin to the production of high-purity active pharmaceutical ingredients (APIs) and finished low molecular weight heparin (LMWH) injections. Its primary product portfolio includes Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Nadroparin Calcium. These products are utilized extensively in the treatment of thromboembolic diseases and as anticoagulants in various clinical settings. The company adheres to international quality management standards and supplies its biochemical solutions to both domestic and global healthcare markets.

Recent filings

Filing Released Lang Actions
北京国枫律师事务所关于公司2025年度股东会的法律意见书
Regulatory Filings Classification · 20% confidence The document is a legal opinion letter (法律意见书) issued by the company’s law firm regarding the legality of the 2025 Annual General Meeting’s convocation, procedures, attendees’ eligibility, and voting results. It is not an Annual Report, proxy statement, or standalone vote announcement, but rather a regulatory/legal compliance filing. It does not include substantive financial statements or serve as the AGM materials themselves, so it falls under the miscellaneous regulatory filings category.
2026-05-19 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the 2025 annual shareholders’ meeting resolutions, detailing each proposal and the vote counts (for, against, abstain) and confirming legal opinions. It specifically reports the voting results from an Annual General Meeting. This aligns with “Declaration of Voting Results & Voting Rights Announcements (DVA).”
2026-05-19 Chinese
关于达肝素钠注射液获得白俄罗斯药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from a foreign regulatory authority (Belarus). It details the product, its uses, and the impact on the company. There is no financial data, no mention of a report or meeting, no voting results, no management changes, no earnings or financial results, and no regulatory certifications or legal proceedings. The document is a regulatory announcement about a product approval, which does not fit into financial report categories but is a regulatory filing. The document length is short and it is an announcement, not a report itself.
2026-05-06 Chinese
关于为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of guarantees provided by the company to its wholly-owned subsidiary. It details the guarantee contract, the financial status of the subsidiary, and the cumulative guarantee amounts. There is no indication that this is a full financial report, audit report, or management discussion. It is a regulatory announcement about financing guarantees, not a report or presentation. The document length is short (1899 characters), and it is a specific update on capital guarantees, which fits best under Capital/Financing Update (CAP).
2026-01-05 Chinese
关于吸收合并全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the absorption merger of a wholly-owned subsidiary by the parent company. It includes details about the merger plan, basic information of both companies, financial data, merger method, and impact on the company. It is a formal corporate announcement about a corporate restructuring event, specifically an absorption merger, and does not contain full financial statements or detailed financial performance reports. It is not an annual or interim report, nor a regulatory certification or voting result. The document is best classified as a Capital/Financing Update (CAP) because it relates to a corporate restructuring transaction involving asset and business consolidation, which affects the company's capital structure and operations.
2025-12-30 Chinese
第六届董事会第六次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the sixth board of directors of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results, and specific board decisions, including the approval of a merger with a wholly-owned subsidiary. There is no financial data, no detailed report, or presentation content. The document is clearly a Board/Management Information announcement about board meeting decisions and changes related to corporate structure. It is not an annual report, audit report, or any other financial report type. Therefore, the appropriate classification is 'MANG' for Board/Management Information.
2025-12-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.